000 | 01989 a2200589 4500 | ||
---|---|---|---|
005 | 20250517130248.0 | ||
264 | 0 | _c20171102 | |
008 | 201711s 0 0 eng d | ||
022 | _a1874-1754 | ||
024 | 7 |
_a10.1016/j.ijcard.2016.11.022 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aLee, Yen-Chieh | |
245 | 0 | 0 |
_aComparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study. _h[electronic resource] |
260 |
_bInternational journal of cardiology _cFeb 2017 |
||
300 |
_a1007-1014 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article | ||
650 | 0 | 4 |
_aAcarbose _xadverse effects |
650 | 0 | 4 | _aAdministration, Oral |
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aCarbamates _xadverse effects |
650 | 0 | 4 | _aCohort Studies |
650 | 0 | 4 | _aConfidence Intervals |
650 | 0 | 4 | _aDatabases, Factual |
650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdiagnosis |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 |
_aHeart Failure _xetiology |
650 | 0 | 4 | _aHospital Mortality |
650 | 0 | 4 |
_aHospitalization _xstatistics & numerical data |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
650 | 0 | 4 | _aIncidence |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aPiperidines _xadverse effects |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aSex Factors |
650 | 0 | 4 |
_aSulfonylurea Compounds _xadverse effects |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 | _aTaiwan |
700 | 1 | _aChang, Chia-Hsuin | |
700 | 1 | _aDong, Yaa-Hui | |
700 | 1 | _aLin, Jou-Wei | |
700 | 1 | _aWu, Li-Chiu | |
700 | 1 | _aHwang, Jing-Shiang | |
700 | 1 | _aChuang, Lee-Ming | |
773 | 0 |
_tInternational journal of cardiology _gvol. 228 _gp. 1007-1014 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ijcard.2016.11.022 _zAvailable from publisher's website |
999 |
_c26671366 _d26671366 |